ABB India Secures Major Contract for Automation Solutions at Reliance Life Sciences
ABB India Limited has recently announced its successful bid for a significant contract with Reliance Life Sciences (RLS). The contract entails the provision of cutting-edge automation control solutions for RLS’s state-of-the-art biosimilars and plasma proteins manufacturing facilities. This development is set to revolutionize pharmaceutical production through the implementation of advanced automation technology.
The biosimilars and plasma proteins manufacturing facilities, sprawling across a vast 160-acre plant in Nashik, Maharashtra, aim to enhance production efficiency and quality control. To achieve this, ABB India will deploy its flagship Distributed Control System (DCS), known as Ability System 800xA, which operates within a virtualized environment. This robust system will seamlessly integrate with various skid systems, facilitating operator interaction, batch control, and real-time production information dissemination on the factory floor.
One of the key highlights of this contract is the deployment of a modular Remote I/O solution, offering flexibility and a plug-and-play approach to automation. This feature is expected to expedite commissioning, process implementation, and potential future expansion of the plant’s capacity. The ability to adapt and expand the manufacturing capabilities is crucial in meeting the industry’s ever-evolving demands.
In addition to these advancements, ABB’s automation solution will include Batch Recipe Management and Integration with a Manufacturing Execution System (MES), streamlining and optimizing the execution of complex manufacturing processes. Through this integrated approach, operational excellence and adherence to strict quality control standards will be achieved, resulting in the production of high-quality pharmaceutical products.
Reliance Life Sciences’ adoption of automation technology is anticipated to yield operational efficiency and reduce the time-to-market for their pharmaceutical products. By implementing ABB’s DCS on the latest Windows Server 2022 platform, Reliance will also mitigate the need for costly plant shutdowns for software upgrades, leading to substantial cost savings.
Compliance with regulatory standards is of utmost importance in the pharmaceutical industry, and Reliance Life Sciences is committed to maintaining high quality throughout its manufacturing process. The installation of ABB’s automation solution strictly adheres to the stringent standards set by the US FDA 21 CFR Part 11. This dedication to regulatory compliance ensures the production of safe and reliable pharmaceutical products.
Beyond enhancing manufacturing processes, ABB’s automation solution will enhance monitoring capabilities throughout different areas of the plant. This will facilitate streamlined maintenance procedures and enable holistic plant management, ensuring seamless coordination between various operational components.
The collaboration between ABB India and Reliance Life Sciences signifies a significant step forward in the automation of pharmaceutical manufacturing. With cutting-edge automation control solutions, Reliance Life Sciences aims to achieve greater operational efficiency, improved product quality, and compliance with regulatory standards. This partnership is set to redefine the future of pharmaceutical production in India and contribute to advancements in the global healthcare industry.
